Japanese pharma giant Taiho invests up to $1.14 billion in Swiss innovation, expanding its portfolio in antibody-drug conjugates …
Japanese pharma giant Taiho invests up to $1.14 billion in Swiss innovation, expanding its portfolio in antibody-drug conjugates …
Long-term clinical data from Roche strengthen the case for disease-modifying therapies in spinal muscular atrophy and Duchenne muscular …
Promising clinical results highlight Gilead’s innovative approach to long-acting HIV treatment, aiming to improve patient adherence and outcomes.
Regeneron and Sanofi bolster their immunology-focused portfolios by acquiring global rights to a promising monoclonal antibody targeting autoimmune …
Amgen advances clinical research with promising data in cardiovascular disease and cancer, reinforcing its commitment to innovation and …
Recent developments underscore innovation in rare diseases and artificial intelligence, reshaping treatment paradigms and accelerating drug development.
Long-term data demonstrate that EBGLYSS offers durable skin improvement and symptom relief, reinforcing its role as a first-line …
Partnerships harnessing artificial intelligence are revolutionizing drug discovery, reducing timelines and improving candidate success rates.
Investments in next-generation manufacturing facilities are unlocking scale, speed, and quality for cell and gene therapies, propelling North …
Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
Already a subscriber? Log in